A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats

Hippocampus

Volumn 18, Issue 2, 2008, Pages 125-134

  Manahan Vaughan, Denise ^a,b   Von Haebler, Dorothea ^c   Winter, Christine ^c   Juckel, Georg ^b,c   Heinemann, Uwe ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Acoustic startle; Dizolcilpine; LTP; Radial maze; Schizophrenia

Indexed keywords

DIZOCILPINE; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; CONTROLLED STUDY; DEFECATION; DELUSION; DENTATE GYRUS; GROOMING; HALLUCINATION; LOCOMOTION; LONG TERM POTENTIATION; MALE; MOOD DISORDER; NERVE CELL PLASTICITY; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; RAT; REARING; REFERENCE MEMORY; SCHIZOPHRENIA; SINGLE DRUG DOSE; SNIFFING; SPATIAL MEMORY; STARTLE REFLEX; STEREOTYPY; WORKING MEMORY; ACUTE DISEASE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; MAZE TEST; MEMORY DISORDER; MOTOR ACTIVITY; ODOR; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ACUTE DISEASE; ANIMALS; ATAXIA; DEFECATION; DENTATE GYRUS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; GROOMING; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMORY DISORDERS; MOTOR ACTIVITY; NEURONAL PLASTICITY; PSYCHOTIC DISORDERS; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SMELL; STARTLE REACTION;

EID: 39849095499     PISSN: 10509631     EISSN: 10981063     Source Type: Journal    
DOI: 10.1002/hipo.20367     Document Type: Article

References (67)

1. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R. 1998. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189-202.
2. Ahlander M, Misane I, Schott PA, Ogren SO. 1999. A behavioral analysis of the spatial learning deficit induced by the NMDA receptor antagonist MK-801 (dizocilpine) in the rat. Neuropsychopharmacology 21:414-426.
3. Andine P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Mårtensson E, Sandberg M. 1999. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 290:1393-1408.
4. Axmacher N, Mormann F, Fernandez G, Elger CE, Fell J. 2006. Memory formation by neuronal synchronization. Brain Res Rev 52:170-182.
5. Bast T, Zhang W, Feldon J, White IM. 2000. Effects of MK801 and neuroleptics on prepulse inhibition: Re-examination in two strains of rats. Pharmacol Biochem Behav 67:647-658.
6. Bliss TV, Collingridge GL. 1993. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 361:31-39.
7. Bliss TVP, Lomo T. 1973. Long-lasting potentiation of synaptic transmission in the dentate area of the anesthetized rabbit following stimulation of the perforant path. J Physiol 232:331-356.
8. Braff DL, Grillon C, Geyer MA. 1992. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49:206-215.
9. Buzsaki G, Draguhn A. 2004. Neuronal oscillations in cortical networks. Science 304:1926-1929.
10. Caine SB, Geyer MA, Swerdlow NR. 1992. Hippocampal modulation of acoustic startle and prepulse inhibition in the rat. Pharmacol Biochem Behav 43:1201-1208.
11. Corbett R. 1995. Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue. Pharmacol Biochem Behav 51:561-564.
12. Davis BM, Beech HR. 1960. The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J Ment Sci 106:912-924.
13. Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J. 2002. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmacol 449:121-125.
14. Dragoi G, Buzsaki G. 2006. Temporal encoding of place sequences by hippocampal cell assemblies. Neuron 50:145-157.
15. Dugladze T, Lepsveridze E, Breustedt J, Kehrer C, Heinemann U, Gloveli T. 2004. Effects of phencyclidines on signal transfer from the entorhinal cortex to the hippocampus in rats. Neurosci Lett 354:185-188.
16. Duncan G, Miyamoto S, Gu H, Lieberman J, Koller B, Snouwaert J. 2002. Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Res 951:166-176.
17. Duncan GE, Moy SS, Lieberman JA, Koller BH. 2006. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol Biochem Behav 85:481-491.
18. Fix AS, Ross JF, Stitzel SR, Switzer RC. 1996. Integrated evaluation of central nervous system lesions: Stains for neurons, astrocytes, and microglia reveal the spatial and temporal features of MK-801-induced neuronal necrosis in the rat cerebral cortex. Toxicol Pathol 24:291-304.
19. Fix AS, Stitzel SR, Ridder GM, Switzer RC. 2000. MK-801 neurotoxicity in cupric silver-stained sections: Lesion reconstruction by 3-dimensional computer image analysis. Toxicol Padiol 28:84-90.
20. Ford JM, Krystal JH, Mathalon DH. 2007. Neural synchrony in schizophrenia: From networks to new treatments. Schizophr Bull 33:848-852.
21. Grace AA. 2000. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Rev 31:330-341.
22. Harris EW, Ganong AH, Cotman CW. 1984. Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. Brain Res 323:132-137.
23. Heale V, Harley C. 1990. MK801 and AP5 impair acquisition but not retention, of the Morris milk maze. Pharmacol Biochem Behav 36:145-149.
24. Healy DJ, Meador-Woodruff JH. 1996. Dopamine receptor gene expression in hippocampus is differentially regulated by the NMDA receptor antagonist MK-801. Eur J Pharmacol 306:257-264.
25. Hoffman DC. 1992. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 89:1-10.
26. Hohnadel E, Bouchard K, Terry AV Jr. 2007. Galantamine and donezepil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacol 52:542-551.
27. Howland JG, MacKenzie EM, Yim TT, Taepavarapruk P, Phillips AG. 2004. Electrical stimulation of the hippocampus disrupts prepulse inhibition in rats: Frequency- and site-dependent effects. Behav Brain Res 152:187-197.
28. Itil T, Keskiner A, Kiremitci N, Holden JMC. 1967. Effect of phencyclidine in chronic schizophrenics. Can J Psychiatr 12:209-212.
29. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
30. Jentsch JD, Roth RH. 1999. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
31. Joyce JN. 1993. The dopamine hypothesis of schizophrenia: Limbic interactions with serotonin and norepinephrine. Psychopharmacol 11(1 Suppl):S16-S34.
32. Kehrer C, Dugladze T, Maziashvili N, Wojtowicz A, Schmitz D, Heinemann U, Gloveli T. 2007. Increased inhibitory input to CA1 pyramidal cells alters hippocampal gamma frequency oscillations in the MK-801 model of acute psychosis. Neurobiol Dis 25:545-552.
33. Kemp A, Manahan-Vaughan D. 2007. Hippocampal long-term depression: Master or minion in declarative memory processes? Trends Neurosci 30:111-118
34. Kim JJ, deCola JP, Landeira-Fernandez J, Fanselow MS. 1991. N-methyl-D-aspartate receptor antagonist, APV blocks acquisition but not expression of fear conditioning. Behav Neurosci 105:126-133.
35. Kulla A, Manahan-Vaughan D. 2000. Depotentiation in the dentate gyrus of freely moving rats is modulated by D1/D5 dopamine receptors. Cereb Cortex 10:614-620.
36. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. 1995. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:869-872.
37. Lukoyanov NV, Paula-Barbosa MM. 2000. A single high dose of dizocilpine produces long-lasting impairment of the water maze performance in adult rats. Neurosci Lett 285:139-142.
38. Manahan-Vaughan D, Reiser M, Pin JP, Wilsch V, Bockaert J, Reymann KG, Riedel G. 1996. Physiological and pharmacological profile of trans-azetidine-2,4-dicarboxylic acid: Metabotropic glutamate receptor agonism and effects on long-term potentiation. Neuroscience 72:999-1008.
39. Manahan-Vaughan D, Braunewell KH, Reymann KG. 1998. Subtypespecific involvement of metabotropic glutamate receptors in two forms of long-term potentiation in the dentate gyrus of freely moving rats. Neuroscience 86:709-721.
40. Miserendino MJD, Sananes CB, Melia KR, Davis M. 1990. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 345:716-718.
41. Morris RGM, Anderson E, Lynch GS, Baudry M. 1986. Selective impairment of learning and blockade if long-term potentiation by an N-methyl- D-aspartate receptor, AP5. Nature 319:774-776.
42. Morris RG, Moser EI, Riedel G, Martin SJ, Sandin J, Day M, O'Carroll C. 2003. Elements of a neurobiological theory of the hippocampus: The role of activity-dependent synaptic plasticity in memory. Philos Trans R Soc Lond B Biol Sci 358:773-786.
43. Naie K, Manahan-Vaughan D. 2004. Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: Relevance for learning and memory formation. Cereb Cortex 14:189-198.
44. Newell KA, Zavitsanou K, Huang XF. 2007. Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. J Neural Transm 114:995-1001.
45. Olney JW, Farber NB. 1995. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
46. O'Neill MF, Sanger GJ. 1999. A single pretreatment with MK-801 or cocaine enhances their locomotor stimulant effects in rats. Brain Res 834:103-111.
47. Park S, Holzmann PS. 1992. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatr 49:975-982.
48. Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. 2005. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 30:633-639.
49. Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, Giegling I, Genius J, McCarley RW, Moller HJ, Grunze H. 2006. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: Molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry 59:721-729.
50. Shapiro ML, Caramanos Z. 1990. NMDA antagonist MK801 impairs acquisition but not performance of spatial working and reference memory. Psychobiology 18:231-243.
51. Sams-Dodd F. 1996. Phencyclidine-induced stereotyped behavior and social isolation in rats: A possible animal model of schizophrenia. Behav Pharmacol 7:3023.
52. Schmajuk NA. 1987. Animal models for schizophrenia: The hippocampally lesioned animal. Schizophr Bull 13:317-327.
53. Schneider M, Koch M. 2002. The cannaboid agonist WIN 55,212 reduces sensorimotor gating and recognition memory in rats. Behav Pharmacol 13:29-23.
54. Schneider M, Koch M. 2003. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacol 28:1760-1769.
55. Schneider M, Koch M. 2005. Behavioral and morphological alterations following neonatal excitoxic lesions of the medial prefrontal cortex. Expl Neurol 195:185-198.
56. Simpson MD, Slater P, Deakin JF, Royston MC, Skan WJ. 1989. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 107:211-215.
57. Spencer KM, Nestor PG, Perlmutter R, Niznikiewicz MA, Klump MC, Frumin M, Shenton ME, McCarley RW. 2004. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci USA 101:17567-17568.
58. Stabenau JR, Pollin W. 1993. Heredity and environment in schizophrenia, revisited. The contribution of twin and high-risk studies. J Nerv Ment Dis 181:290-297.
59. Staubli U, Thibault O, DiLorenzo M, Lynch G. 1989. Antagonism of NMDA receptors impairs acquisition but not retention of olfactory memory. Behav Neurosci 103:54-60.
60. Sturgeon RD, Fessler RG, Meltzer HY. 1979. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 59:169-179.
61. Swerdlow NR, Braff DL, Geyer MA, Koob GF. 1986. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiatry 21:23-33.
62. Tamlyn D, McKenna PJ, Mortimer AM, Lund CE, Hammond S, Baddeley AD. 1992. Memory impairment in schizophrenia: Its extent, affiliations and neuropsychological character. Psychol Med 22:101-115.
63. Tiedtke PI, Bischoff C, Schmidt WJ. 1990. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm Gen Sect 81:173-182.
64. Weinberger DR. 1999. Cell Biology of the hippocampal formation in Schizophrenia. Biol Psychiatr 45:395-402.
65. Welzl H, Alessandri B, Battig K. 1990. The formation of a new gustatory memory trace in rats is prevented by the noncompetitive NMDA antagonist ketamine. Psychobiology 18:43-47.
66. Whishaw IQ, Auer RN. 1989. Immediate and long-lasting effects of MK-801 on motor activity, spatial navigation in a swimming pool and EEG in the rat MK-801 neurotoxicity in male mice: Histologic effects and chronic impairment in spatial learning. Psychopharmacology (Berl) 98:500-507.
67. Willner P. 1997. The dopamine hypothesis of schizophrenia: Current status, future prospects. Int Clin Psychopharmacol 12:297-308.